Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Kyleena is a prescription levonorgestrel-releasing intrauterine system used to prevent pregnancy for up to five years. The T-shaped device contains 19.5 mg of levonorgestrel and is inserted into the uterus by a trained healthcare professional.
read more about kyleena ...Kyleena releases levonorgestrel mainly within the uterus. Its contraceptive activity is associated with thickening of cervical mucus, reduced sperm survival or movement, and changes in the endometrium. Ovulation continues in a substantial proportion of users.
Kyleena is used by females of reproductive potential who choose an intrauterine contraceptive. It is contraindicated during known or suspected pregnancy and in selected uterine abnormalities, pelvic infections, unexplained uterine bleeding, progestin-sensitive cancer, acute liver disease, and several other conditions listed in current labeling.
Kyleena releases about 17.5 mcg of levonorgestrel per day after 24 days, declining to about 7.4 mcg per day after five years. The device is removed or replaced by the end of the fifth year. A follow-up examination is recommended four to six weeks after insertion and then yearly or as clinically indicated.
Serious concerns include ectopic pregnancy if conception occurs with the device in place, pelvic infection, sepsis, uterine perforation, and partial or complete expulsion. Ovarian cysts and changes in bleeding patterns can also occur. Kyleena does not protect against sexually transmitted infections.
Kyleena is labeled for pregnancy prevention for up to five years.
The intrauterine system contains 19.5 mg of levonorgestrel.
A trained healthcare professional inserts Kyleena using the supplied sterile inserter.
No. Kyleena does not protect against HIV or other sexually transmitted infections.
DailyMed - KYLEENA (levonorgestrel) intrauterine device. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e07c155-21e1-4781-9633-ce8bddd47080. Date Accessed October 8, 2026.
KYLEENA (levonorgestrel-releasing intrauterine system) Approval Letter. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/208224Orig1s000ltr.pdf. Date Accessed October 8, 2026.
KYLEENA (levonorgestrel-releasing intrauterine system) Prescribing Information. Bayer. https://labeling.bayerhealthcare.com/html/products/pi/Kyleena_PI.pdf. Date Accessed October 8, 2026.
Levonorgestrel. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Levonorgestrel. Date Accessed October 8, 2026.
Levonorgestrel Intrauterine System. MedlinePlus. https://medlineplus.gov/druginfo/meds/a613047.html. Date Accessed October 8, 2026.